Acrivon Therapeutics ACRV
NASDAQ ACRV
$1.57 +0.00 (+0.00%)
At close: Nov 11, 2026 · 4:00 PM EST

Acrivon Therapeutics (ACRV) Preferred Stock Liabilities (2021 - 2022)

Updated

Acrivon Therapeutics' Preferred Stock Liabilities came in at $122.52 million for Q3 2022, up 444.5% from $22.5 million a year earlier and unchanged from the prior quarter.

Analysis

Acrivon Therapeutics (ACRV) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends

Going back to Q3 2021, Acrivon Therapeutics' Preferred Stock Liabilities data covers 5 quarters.

  • Business Quant data shows ACRV's Preferred Stock Liabilities at $122.52 million (Q2 2022), $122.52 million (Q1 2022) and $122.52 million (Q4 2021) in the three quarters before Q3 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Acrivon Therapeutics 67.27 Mn -368.26 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 122.52 Mn
Jun 30, 2022 122.52 Mn
Mar 31, 2022 122.52 Mn
Dec 31, 2021 122.52 Mn
Sep 30, 2021 22.50 Mn
API Access

Acrivon Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ACRV&period=max&api_key=YOUR_API_KEY